Related Experiment Videos
Angiogenesis modulation in cancer research: novel clinical approaches
Massimo Cristofanilli1, Chusilp Charnsangavej, Gabriel N Hortobagyi
1Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. mcristof@mdanderson.org
Abstract:
Angiogenesis--the formation of new blood vessels--is essential for tumour progression and metastasis. Consequently, the modulation of tumour angiogenesis using novel agents has become a highly active area of investigation in cancer research, from the bench to the clinic. However, the great therapeutic potential of these agents has yet to be realized, which could, in part, be because the traditional strategies that are used in clinical trials for anticancer therapies are not appropriate for assessing the efficacy of agents that modulate angiogenesis. Here, we discuss methods for monitoring the biological activity of angiogenic modulators, and innovative approaches to trial design that might facilitate the integration of these agents into anticancer therapy.
Insights
Targeting tumor angiogenesis, the formation of new blood vessels, is crucial in cancer. New clinical trial strategies are needed to effectively evaluate novel anti-angiogenic agents for cancer therapy.
Area of Science:
- Oncology
- Cancer Biology
- Vascular Biology
Background:
- Angiogenesis, the formation of new blood vessels, is vital for tumor growth and metastasis.
- Modulating tumor angiogenesis with novel agents is a key focus in cancer research.
- Current clinical trial strategies may not be optimal for assessing anti-angiogenic agents.
Purpose of the Study:
- To discuss methods for monitoring the biological activity of angiogenic modulators.
- To propose innovative clinical trial designs for anti-angiogenic therapies.
Main Methods:
- Review of current methods for assessing anti-angiogenic agent activity.
- Discussion of novel approaches in clinical trial design for cancer therapies.
Main Results:
- Traditional clinical trial methods may not adequately measure the efficacy of angiogenesis modulators.
- Innovative monitoring and trial design are necessary for successful integration of these agents.
Conclusions:
- Effective evaluation of anti-angiogenic agents requires specialized monitoring techniques.
- Adapting clinical trial designs is essential to realize the therapeutic potential of novel anti-angiogenic therapies in cancer treatment.